2 results
Approved WMOCompleted
To assess the safety, reactogenicity, and tolerability of increasing GEM intranasal doses (1.25 mg, 2.5 mg and 5.0 mg) and intramuscular doses (0.05, 0.1, 0.2 mg) of the GEM adjuvant, each administration containing as well a standard 2010/2011 Flu…
Approved WMORecruiting
We aim to determine the specificity of radiolabelled exendin during the course of T2D and to examine the role of glycemic control on the correlation between pancreatic 111In-exendin uptake, BCM and GLP-1R expression in patients with T2D undergoing (…